伊卡帕B激酶通过抑制分叉FOXO3a的作用促进瘤发生
Mickey C-T Hu1, Dung-Fang Lee, Weiya Xia
1Department of Molecular and Cellular Oncology, The University of Texas, Houston, TX 77030, USA. michu@mdanderson.org
Cell
|April 16, 2004
概括
通常由Akt调节的FOXO3a的核排斥也可以通过IKK独立地发生. 这种IKK介导的途径促进细胞增殖和瘤发生,影响乳腺癌的存活率.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 细胞信号传递 细胞信号传递
背景情况:
- 沟转录因子FOXO3a通常被Akt从细胞核中排除,从而促进细胞的存活.
- 以前的理解将FOXO3a核排斥仅与Akt酸化联系在一起.
研究的目的:
- 在初级瘤中研究酸化-Akt (Akt-p) 和FOXO3a之间的病理关系.
- 为了确定规范FOXO3a局部化超出Akt信号的替代机制.
主要方法:
- 分析原发性瘤以评估Akt-p和FOXO3a的局部化.
- 在体外实验表明IkappaB激酶 (IKK) 与FOXO3a.a的相互作用,酸化和抑制.
- 通过Ub-依赖的蛋白酶体路径对FOXO3a蛋白解的研究.
- 细胞质FOXO3a与IKKbeta或Akt-p表达的相关性分析.
- 评估IKKbeta对细胞增殖和瘤发生的影响,以及FOXO3a在这个过程中的作用.
主要成果:
- 在一些缺乏Akt-p的瘤中,FOXO3a被发现被排除在核之外,这表明Akt-独立的机制.
- 伊卡帕B激酶 (IKK) 已被证明与物理相互作用,酸化,并抑制FOXO3a独立于Akt.
- 通过IKK介导的FOXO3a抑制导致其通过Ub-依赖的蛋白酶体路径进行蛋白质分解.
- 细胞质FOXO3a与IKKbeta或Akt-p表达相关,并且与乳腺癌的生存率差相关.
- 构成性IKKbeta表达促进细胞增殖和瘤发生,这些效应可以通过FOXO3a抵消.
结论:
- 伊卡帕B激酶 (IKK) 代表了对FOXO3a定位和功能的负调节的新途径.
- 这种IKK介导的FOXO3a的细胞质局部化是促进细胞生长和瘤发生的关键机制.
- 这些发现揭示了IKK在癌症发展中的关键作用,独立于成熟的Akt路径.
更多相关视频
相关概念视频
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...


